Endocrine and metabolic effects of non steroidal anti-inflammatory therapy in overweight, hypogonadal men with obstructive sleep apnea: A pilot study

Trial Profile

Endocrine and metabolic effects of non steroidal anti-inflammatory therapy in overweight, hypogonadal men with obstructive sleep apnea: A pilot study

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Celecoxib (Primary)
  • Indications Hypogonadism; Obesity; Sleep apnoea syndrome
  • Focus Pharmacodynamics
  • Acronyms INFLATE
  • Most Recent Events

    • 17 Jul 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by Australian New Zealand Clinical Trials Registry.
    • 05 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top